Skip to main navigation

menu

Vision and Leadership
Science and Pipeline
Commitment
Investors
- « Back
People
Contact

Vision and Leadership
Science and Pipeline
Commitment
Investors
- « Back
People
Contact

for investors

Ovid Hosts Conference Call to Discuss Strategic Transaction

Mar 3, 2021 8:30 AM EST

Click here for webcast

Site - Investor Relations - 2nd Tier

Overview
Stock Information
- Stock Quote
- Analyst Coverage
News & Events
- Press Releases
- Presentations & Events
Governance
- Governance
- Committee Composition
Financials
- SEC Filings
- Reports & Results
Investor Resources

Site - Investor Relations - 3rd Tier

Overview
Stock Information
- Stock Quote
- Analyst Coverage
News & Events
- Press Releases
- Presentations & Events
Governance
- Governance
- Committee Composition
Financials
- SEC Filings
- Reports & Results
Investor Resources

Press Releases

Press Releases

Year

Mar 03, 2021 Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome

Pagination

First page
Previous page
Page 1
Page 2
Current page 3

Site - Stockholder Tools

Print Page RSS Feeds Share Page E-mail Alerts

Site - Footer Nav

Contact
Privacy Policy
Terms & Conditions Agreement
Community Guidelines
Third-Party Websites

Site - Footer - Social icons

Linkedin
Twitter
Webcast
Youtube
Facebook

© Copyright 2021 Ovid Therapeutics.

Ovid, Ovid Therapeutics, Ovid Therapeutics Inc., and BoldMedicine are trademarks of Ovid Therapeutics Inc. All rights reserved.

Site - Footer - Social icons

Linkedin
Twitter
Webcast
Youtube
Facebook

Share on:
Facebook
Twitter
LinkedIn
Reddit
Digg
Google
StumbleUpon
What's This?
Share this page through your favorite social channel or email this page to a colleague.